SLC5A2 and heart failure: Similarly, SGLT2 inhibitors have been validated in trials such as EMPA-REG OUTCOME [37], CANVAS [38], and DAPA-HF [39], which highlighted their benefits in reducing cardiovascular death, heart failure hospitalizations, and progression of renal disease.